

## Service Profile

# miRNA Sequencing Service

Robust differential expression analysis along with novel miRNA discovery, enabling you to further your goals

Profiling of miRNAs holds great promise due to their potential use as biomarkers for various diseases. Still, a number of limitations are associated with miRNA profiling. QIAGEN® Genomic Services overcomes these limitations by combining our innovative QIAseq® miRNA-seq technology with decades of technical expertise across a large variety of challenging samples. Extend your in-house resources with the expertise and high quality services you can expect from QIAGEN.

Our all-in-one miRNA Sequencing Service offers the following benefits:

- **End-to-end service:** We take care of every step, from sample preparation to data analysis
- **Highly efficient library preparation:** Bead-based method removing adapter dimers and unwanted RNA species
- **Elimination of PCR duplication and sequencing bias:** Unique Molecular Indices (UMIs) allowing for quantification of single miRNA molecules
- **Ready-to-publish data:** We deliver comprehensive reports and data packages, and provide guidance on the next steps

Partner with us for expert guidance and dedicated service – from Sample to Insight® – for profiling your samples today.






Figure 1. Sample to Insight miRNA Sequencing Service workflow.



**Figure 2. QIAseq miRNA Library Kit workflow.** Optimized reaction chemistry enables robust, miRNA-specific libraries while minimizing reaction biases and eliminating adapter dimers. Unique Molecular Indices (UMIs) tag each miRNA at an early stage, eliminating PCR and sequencing bias.

## Bioinformatics: a bridge between data and discovery

Novel insights often remain elusive without the right tools and expertise for data analysis and interpretation. QIAGEN Genomic Services uses industry-leading pipelines and best-in-class algorithms to provide you with the answers to your biological questions. The examples provided below show data analysis results including publication-grade graphs and figures which are part of the Genomic Services deliverables.



**Figure 3. Principal component analysis (PCA) – sample clustering based on the expression profile.** The data points that represent the samples are projected onto a two-dimensional plane such that they spread out in the two directions that explain most of the differences. A variance-stabilizing transformation is performed on the raw count matrix, and 500 genes with the highest variance are used to plot the PCA.




Figure 4. Hierarchical clustering – identification of gene expression patterns. A variance-stabilizing transformation was performed on the raw count matrix, and 35 miRNAs with the highest variance across samples were selected for hierarchical clustering. Each row represents one specific miRNA and each column represents one sample. The color represents the difference of the count value to the row mean.












Figure 5. Differential gene expression. For each differential gene expression analysis, the result of the statistical test is represented in a separate MA plot. Each gene's fold-change is plotted against its mean expression among all samples. All significantly differentially expressed miRNAs are marked in red. Significant changes are defined as false discovery rate (FDR) < 0.01.

## Service specifications

<b>Consultation</b> 	Free consultation with an expert to design an experimental setup that best meets your needs.		
<b>Sample requirements</b> 	<b>Sample input</b> Customer-isolated RNA  Cells  Fresh frozen tissue  FFPE  Blood (PAXgene)  Other	<b>Isolation kit</b> N/A  miRNeasy Mini  RNeasy Plus Universal (total RNA including miRNA)  miRNeasy FFPE  PAXgene Blood miRNA  Please inquire	<b>Input requirements</b> Minimum: 160 ng total RNA (>10 ng/μl) Recommended: 300 ng total RNA OD <sub>260</sub> /OD <sub>280</sub> value >1.6 RIN value >7  Minimum: 2 x 10 <sup>6</sup> cells, pelleted and frozen  Minimum: 5 mg Maximum: 50 mg  Minimum: 2 x 10 μm sections of 250 mm <sup>2</sup> Maximum: 4 x 10 μm sections of 250 mm <sup>2</sup>  Recommended: 1 tube
<b>Sample quality control</b> 	Fluorescence-based dye for determination of sample concentration Gel electrophoresis for determination of RNA integrity (e.g., RIN value from capillary gel electrophoresis) This is a STOP/GO point where it is possible to omit samples or replace samples before proceeding		
<b>Library preparation and quality control</b> 	Library preparation using QIAseq miRNA Library Kit Integrated UMI technology Gel-free, bead-based size selection (15–40 nt) Library quality control by gel electrophoresis to check for the right fragment size and concentration This is a STOP/GO point where it is possible to omit samples before proceeding		
<b>Sequencing parameters</b> 	Illumina NextSeq® or Illumina NovaSeq® systems Single-end reads Read length of 75 bp Read depth of 12million reads on average		
<b>Complete data analysis</b> 	Raw data  Raw data quality control  Filtering and deduplication  Mapping miRbase (v22) and small RNA databases	De-multiplexed FASTQ files  CLC graphical QC report (for each sample) CLC supplementary QC report (for each sample)  UMI report (for each sample) Removal of adapters, low-quality, short sequences and ambiguous nucleotides Deduplication statistics  miRNA quantification report (for each sample and for combined samples) Mapping rates and annotation statistics Spike-in information included when applicable  Raw counts matrix  CPM-normalized counts matrix	FASTQ.GZ  PDF Excel  PDF  Excel  Excel Excel

<p><b>Complete data analysis</b></p> 	<p>Mapping genome (GRCh38 for human)</p> <p>Reads that do not map to miRBase with perfect complementarity or as isomiRs are mapped to the genome (if available). No differential expression analysis is provided on extra annotation.</p>	<p>RNA-seq report</p> <p>Raw counts matrix</p> <p>TPM-normalized counts matrix</p>	<p>PDF</p> <p>Excel</p> <p>Excel</p>
	<p>Unsupervised analysis of miRNA expression</p>	<p>PCA plot</p> <p>Hierarchical clustering and heatmap</p>	<p>PDF</p> <p>PDF</p>
	<p>Differential expression for miRNAs</p> <p>Maximum 10 defined comparisons. Inquire for additional analysis.</p>	<p>Differential expression statistics for each defined comparison</p> <p>Fold-change, log<sub>2</sub> FC, p-value, FDR-corrected p-value, Bonneferoni corrected values</p> <p>MA plot</p>	<p>Excel</p> <p>PDF</p>
	<p>Species supported</p>	<p>All species published in miRbase (v22): <a href="http://www.mirbase.org/index.shtml">http://www.mirbase.org/index.shtml</a> are supported. <b>Inquire</b> for other species.</p>	
	<p>Pathway analysis</p>	<p>QIAGEN Ingenuity Pathway Analysis® (IPA®) miRNA-only projects include limited analysis. miRNA combined with whole transcriptome and mRNA data are recommended for full IPA analysis. IPA analysis is available as an add-on; refer to IPA demo report. Supported for human, rat and mouse. <b>Inquire</b> for other species.</p>	<p>Various</p>
	<p>Merge data with data from previous projects</p>	<p><b>Inquire</b></p>	
	<p>Data delivery</p>	<p>Encrypted USB/HDD or cloud delivery</p>	
	<p><b>Final report and consultation</b></p> 	<p>Final data analysis package contains the following:</p> <ul style="list-style-type: none"> <li>• Overview of data analysis and algorithms used</li> <li>• Files and tables listed under “Complete data analysis”</li> <li>• Publication-ready figures are typically provided as PDF. <b>Inquire</b> for SVG or other formats.</li> </ul> <p>Teleconference with QIAGEN scientists to discuss analysis and validation of results. Consultation and support will be provided for 90 days following delivery of data (for data-delivery-only projects) or delivery of data analysis (for data-analysis-inclusive projects). <b>Inquire</b> for extended support beyond 90 days.</p>	

**Note:** Service specifications might be tailored to the needs of the project on a case-by-case basis.

# How can we accelerate your research?

Our expert team is looking forward to learning about your research project and designing your customized service with QIAGEN.



The QIAGEN® Genomics Service is intended exclusively for research use only (RUO). This service is not intended for the diagnosis, prevention or treatment of a disease.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at [www.qiagen.com](http://www.qiagen.com) or can be requested from QIAGEN Technical Services or your local distributor.

Trademarks: QIAGEN®, Sample to Insight®, QIAseq®, Ingenuity Pathway Analysis®, IPA®, PAXgene®, RNeasy® (QIAGEN Group); Illumina®, NextSeq®, NovaSeq® (Illumina, Inc.). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, may still be protected by law.

© 2022 QIAGEN, all rights reserved. PROM-18122-001

Ordering [www.qiagen.com/shop](http://www.qiagen.com/shop) | Technical Support [support.qiagen.com](http://support.qiagen.com) | Website [www.qiagen.com](http://www.qiagen.com)